82_FR_10809 82 FR 10779 - Government-Owned Inventions; Availability for Licensing

82 FR 10779 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 30 (February 15, 2017)

Page Range10779-10780
FR Document2017-03016

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 30 (Wednesday, February 15, 2017) 
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10779-10780]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03016]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis

    Description of Technology: Malaria is the single leading cause of 
mortality, especially among children in the developing world. Typhoid 
fever, caused by infection with Salmonella typhi, is known to be 
endemic with malaria and causes its own significant disease burden. 
Scientists at the National Institute of Allergy and Infectious Diseases 
(NIAID), part of the National Institutes of Health, have developed a 
novel bivalent vaccine candidate that may effectively prevent malaria 
and typhoid. This approach significantly enhances immune response to 
the Pfs25 Malaria transmission blocking antigen and produces a robust 
immune response against Salmonella typhi Vi polysaccharide (ViP).
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Development of this technology into a vaccine may protect 
vulnerable populations from both Malaria transmission and Typhoid 
fever.
    Competitive Advantages:
     This technology has significant advantages over current 
treatments, since there is currently only one commercial Malaria 
vaccine licensed for use in Europe only, which was not developed to 
address Malaria transmission, and the currently licensed Salmonella 
typhi vaccines show incomplete efficacy and do not provide long-term 
immunity. A formulation of the present technology has shown the ability 
to induce an immune response to Pfs25 in excess of 100 times higher and 
Salmonella typhi antigen 20-40 times higher than what is seen by 
immunization with either antigen alone.
    Development Stage:
     In vivo data available (animal).
    Inventors: Drs. Patrick Duffy, Sojung An, and Puthupparampil 
Scaria, NIAID, NIH.
    Publications: None.
    Intellectual Property: Provisional Patent application #62/327,184 
Filed 04/25/16, Technology reference #E-124-2016/0.

[[Page 10780]]

    Licensing Contact: Daniel Anacker, Ph.D., 301-761-7671, 
[email protected].
    Collaborative Research Opportunity: The NIAID, Laboratory of 
Malaria Immunology and Vaccinology is seeking statements of capability 
or interest from parties interested in collaborative research to 
further develop, evaluate, or commercialize this technology. Please 
contact Dr. Daniel Anacker at 301-761-7671 or [email protected] 
for more information.

    Dated: February 8, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03016 Filed 2-14-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices 10779 licensing to achieve expeditious • Potential one-dose flavivirus vaccine 301–496–2644. A signed Confidential commercialization of results of • Ease of manufacture in Vero cells Disclosure Agreement will be required federally-funded research and • Low-cost potential vaccine to receive copies of unpublished patent development. Foreign patent • Developing and developed world applications. applications are filed on selected potential vaccines SUPPLEMENTARY INFORMATION: inventions to extend market coverage Development Stage: Technology description follows. for companies and may also be available • In vivo data available (animal) for licensing. A Bivalent Conjugate Vaccine for Inventors: Alexander Pletnev (NIAID), Malaria and Typhoid Prophylaxis FOR FURTHER INFORMATION CONTACT: Konstantin Tsetsarkin (NIAID). Licensing information and copies of the Intellectual Property: HHS Reference Description of Technology: Malaria is patent applications listed below may be No. E–006–2017/0—U.S. Provisional the single leading cause of mortality, obtained by communicating with the Application No. 62/443,214, filed especially among children in the indicated licensing contact at the January 6, 2017. developing world. Typhoid fever, Technology Transfer and Intellectual Licensing Contact: Peter Soukas, J.D., caused by infection with Salmonella Property Office, National Institute of 301–594–8730; peter.soukas@nih.gov. typhi, is known to be endemic with Allergy and Infectious Diseases, 5601 Collaborative Research Opportunity: malaria and causes its own significant Fishers Lane, Rockville, MD 20852; tel. The National Institute of Allergy and disease burden. Scientists at the 301–496–2644. A signed Confidential Infectious Diseases is seeking statements National Institute of Allergy and Disclosure Agreement will be required of capability or interest from parties Infectious Diseases (NIAID), part of the to receive copies of unpublished patent interested in collaborative research to National Institutes of Health, have applications. further develop, evaluate or developed a novel bivalent vaccine SUPPLEMENTARY INFORMATION: commercialize vaccine(s) for candidate that may effectively prevent Technology description follows. prophylaxis against flavivirus malaria and typhoid. This approach infections. For collaboration significantly enhances immune Synergistic Internal Ribosomal Entry opportunities, please contact Peter response to the Pfs25 Malaria Site (IRES)—MicroRNA-Based Soukas, J.D., 301–594–8730; transmission blocking antigen and Approach for Attenuation of peter.soukas@nih.gov. produces a robust immune response Flaviviruses and Live Vaccine against Salmonella typhi Vi Development Dated: February 6, 2017. polysaccharide (ViP). Description of Technology: Many Suzanne Frisbie, This technology is available for members of the Flaviviridae family are Deputy Director, Technology Transfer and licensing for commercial development emerging and reemerging human Intellectual Property Office, National Institute in accordance with 35 U.S.C. 209 and 37 pathogens that have caused outbreaks of of Allergy and Infectious Diseases. CFR part 404, as well as for further devastating and often fatal diseases and [FR Doc. 2017–03017 Filed 2–14–17; 8:45 am] development and evaluation under a represent a serious public health BILLING CODE 4140–01–P research collaboration. problem on a global scale. There is no Potential Commercial Applications: single attenuation strategy that exists DEPARTMENT OF HEALTH AND • Development of this technology which is sufficient to prepare a safe, HUMAN SERVICES into a vaccine may protect vulnerable efficacious and immunogenic live populations from both Malaria attenuated virus vaccine that will work National Institutes of Health transmission and Typhoid fever. universally for Flaviviridae. This patent application claims live attenuated Competitive Advantages: Government-Owned Inventions; • This technology has significant flavivirus vaccines, live attenuated Availability for Licensing multivalent flavivirus vaccines, and advantages over current treatments, methods of preventing flavivirus AGENCY: National Institutes of Health, since there is currently only one infections as well as methods of making HHS. commercial Malaria vaccine licensed for the vaccines claimed in the application. use in Europe only, which was not ACTION: Notice. More specifically, this patent developed to address Malaria application claims methods for SUMMARY: The invention listed below is transmission, and the currently licensed attenuating a flavivirus or chimeric owned by an agency of the U.S. Salmonella typhi vaccines show flavivirus using a synergistic dual Government and is available for incomplete efficacy and do not provide strategy involving inserting miRNA- licensing to achieve expeditious long-term immunity. A formulation of targeting sequences to restrict virus commercialization of results of the present technology has shown the replication in target hosts, cells and/or federally-funded research and ability to induce an immune response to tissues and placing one or more development. Foreign patent Pfs25 in excess of 100 times higher and flavivirus genes under translational applications are filed on selected Salmonella typhi antigen 20–40 times control of an internal ribosomal entry inventions to extend market coverage higher than what is seen by site (IRES). for companies and may also be available immunization with either antigen alone. This technology is available for for licensing. Development Stage: licensing for commercial development FOR FURTHER INFORMATION CONTACT: • In vivo data available (animal). in accordance with 35 U.S.C. 209 and 37 Licensing information and copies of the Inventors: Drs. Patrick Duffy, Sojung mstockstill on DSK3G9T082PROD with NOTICES CFR part 404, as well as for further patent applications listed below may be An, and Puthupparampil Scaria, NIAID, development and evaluation under a obtained by communicating with the NIH. research collaboration. indicated licensing contact at the Publications: None. Potential Commercial Applications: Technology Transfer and Intellectual Intellectual Property: Provisional • Diagnostics Property Office, National Institute of Patent application #62/327,184 Filed • Vaccines Allergy and Infectious Diseases, 5601 04/25/16, Technology reference #E– Competitive Advantages: Fishers Lane, Rockville, MD 20852; tel. 124–2016/0. VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1

10780 Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices Licensing Contact: Daniel Anacker, submitted by one of the following Technologies Strategic Vision Ph.D., 301–761–7671, daniel.anacker@ methods: Subcommittee’s study of the near- and nih.gov. • Federal eRulemaking Portal: http:// longer-term NS/EP implications of Collaborative Research Opportunity: www.regulations.gov. Please follow the emergent and expected information and The NIAID, Laboratory of Malaria instructions for submitting written communications technologies. Immunology and Vaccinology is seeking comments. Dated: February 2, 2017. statements of capability or interest from • Email: NSTAC@hq.dhs.gov. Include Helen Jackson, parties interested in collaborative the docket number DHS–2017–0005 in Designated Federal Officer for the NSTAC. research to further develop, evaluate, or the subject line of the email. commercialize this technology. Please • Fax: (703) 235–5962, ATTN: Sandy [FR Doc. 2017–03009 Filed 2–14–17; 8:45 am] contact Dr. Daniel Anacker at 301–761– Benevides. BILLING CODE 9110–9P–P 7671 or daniel.anacker@nih.gov for • Mail: Designated Federal Officer, more information. Stakeholder Engagement and Critical Infrastructure Resilience Division, INTERNATIONAL BOUNDARY AND Dated: February 8, 2017. National Protection and Programs WATER COMMISSION UNITED Suzanne Frisbie, STATES AND MEXICO Directorate, Department of Homeland Deputy Director, Technology Transfer and Security, 245 Murray Lane, Mail Stop Intellectual Property Office, National Institute United States Section; Notice of of Allergy and Infectious Diseases. 0604, Arlington, VA 20598–0604. Instructions: All submissions received Availability of a Final Environmental [FR Doc. 2017–03016 Filed 2–14–17; 8:45 am] Assessment and Finding of No must include the words ‘‘Department of BILLING CODE 4140–01–P Homeland Security’’ and the docket Significant Impact for Alamito and number for this action. Comments Terneros Sediment and Vegetation received will be posted without Removal Below Presidio Flood Control DEPARTMENT OF HOMELAND alteration at www.regulations.gov, Project, Presidio, Texas SECURITY including any personal information AGENCY: United States Section, provided. International Boundary and Water [Docket No. DHS–2017–0005] Docket: For access to the docket and Commission, United States and Mexico. The President’s National Security comments received by the NSTAC, ACTION: Notice of Availability of the Telecommunications Advisory please go to www.regulations.gov and Final Environmental Assessment (EA) Committee enter docket number DHS–2017–0005. and Finding of No Significant Impact A public comment period will be held (FONSI). AGENCY: Department of Homeland during the conference call on Friday, Security. March 3, 2017, from 12:40 p.m. to 12:55 SUMMARY: Pursuant to Section 102(2)(c) ACTION: Committee Management; Notice p.m. EST. Speakers who wish to of the National Environmental Policy of Federal Advisory Committee Meeting. participate in the public comment Act of 1969; the Council on period must register in advance and can Environmental Quality Final SUMMARY: The President’s National do so by emailing NSTAC@hq.dhs.gov Regulations (40 CFR parts 1500 through Security Telecommunications Advisory no later than Monday, February 27, 1508); and the United States Section, Committee (NSTAC) will meet via 2017, at 5:00 p.m. EST. Speakers are Operational Procedures for teleconference on Friday, March 3, requested to limit their comments to Implementing Section 102 of NEPA, 2017. The meeting will be open to the three minutes and will speak in order of published in the Federal Register public. registration. Please note that the public September 2, 1981 (46 FR 44083); the DATES: The NSTAC will meet on Friday, comment period may end before the United States Section hereby gives March 3, 2017, from 12:00 p.m. to 1:00 time indicated, following the last notice that the Final Environmental p.m. Eastern Standard Time (EST). request for comments. Assessment and Finding of No Please note that the meeting may close FOR FURTHER INFORMATION CONTACT: Significant Impact (FONSI) for Alamito early if the committee has completed its Helen Jackson, NSTAC Designated and Terneros Sediment and Vegetation business. Federal Officer, Department of Removal below Presidio Flood Control ADDRESSES: The meeting will be held Homeland Security, (703) 235–5321 Project, Presidio, Texas is available. An via conference call. For access to the (telephone) or helen.jackson@ environmental impact statement will conference call bridge, information on hq.dhs.gov (email). not be prepared unless additional services for individuals with SUPPLEMENTARY INFORMATION: Notice of information which may affect this disabilities, or to request special this meeting is given under the Federal decision is brought to our attention assistance to attend, please email Advisory Committee Act, 5 U.S.C. within 30-days from the date of this NSTAC@hq.dhs.gov by 5:00 p.m. EST appendix (Pub. L. 92–463). The NSTAC Notice. on Monday, February 27, 2017. advises the President on matters related FOR FURTHER INFORMATION CONTACT: Members of the public are invited to to national security and emergency Gilbert Anaya, Division Chief, provide comment on the issues that will preparedness (NS/EP) Environmental Management Division; be considered by the committee as listed telecommunications and cybersecurity United States Section, International in the SUPPLEMENTARY INFORMATION policy. Boundary and Water Commission; 4171 section below. Associated briefing Agenda: The NSTAC will hold a N. Mesa, C–100, El Paso, Texas 79902. mstockstill on DSK3G9T082PROD with NOTICES materials that participants may discuss conference call on March 3, 2017, to Telephone: (915) 832–4702, email: during the meeting will be available at discuss issues and challenges related to Gilbert.Anaya@ibwc.gov. www.dhs.gov/nstac for review as of NS/EP communications, which will Background: This Final Friday, February 24, 2017. Comments include discussions with high-level Environmental Assessment analyzes the may be submitted at any time and must Government stakeholders and a review potential impacts of removing be identified by docket number DHS– of ongoing NSTAC work, including an accumulated sediment from Alamito 2017–0005. Comments may be update on the NSTAC Emerging and Terneros Creeks at their confluence VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1


Document Created: 2017-02-15 00:55:10
Document Modified: 2017-02-15 00:55:10
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 10779 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR